BPC-157
Synthetic pentadecapeptide · Also written BPC 157, Bepecin, PL 14736
- UK status
- Unlicensed medicine
- Availability
- Research use only
- Evidence base
- Animal studies, almost no human data
- Controlled drug
- No, but WADA prohibited
Peptide sequence, one-letter notation
GEPPPGKPADDAGLV
BPC-157 is the compound that best illustrates the gap between what the internet says about peptides and what has actually been tested in people. There is a large body of animal research and there is almost nothing in humans.
01What it is
BPC-157 is a synthetic chain of 15 amino acids, described in the literature as a stable gastric pentadecapeptide. Its sequence derives from a fragment of a protein found in human gastric juice.
It is not a GLP-1 drug and has nothing to do with weight loss. It gets grouped with them only because both fall under the word "peptide", which is the single biggest source of confusion in this whole subject.
02UK legal and licensing status
BPC-157 is an unlicensed medicine in the UK. It is not approved by the MHRA, the EMA or the FDA for any human use. It is not a controlled drug under the Misuse of Drugs Act, but supplying or marketing it for human use without authorisation is prohibited under the Human Medicines Regulations 2012. It cannot be lawfully prescribed.
It is sold legally as a research chemical, labelled "not for human consumption". That label is a legal position taken by the seller, not a statement about product quality, and it is the mechanism by which an unlicensed medicine reaches consumers who are not researchers.
In April 2026 the MHRA opened an investigation into UK clinics making therapeutic claims about unregulated peptides. BPC-157 was reported as the first compound named.
Athletes: WADA lists BPC-157 under S0, unapproved substances, prohibited at all times both in and out of competition. Detection methods have been published. Strict liability applies, so there is no timing strategy that makes it safe for a tested athlete.
03How it works
Proposed mechanisms come from animal work and are not settled. The most frequently cited involve effects on blood vessel formation, growth factor expression and nitric oxide signalling in damaged tissue.
Be careful with how this is presented elsewhere. A proposed mechanism from rodent studies is often described online as though it were an established action in humans. Those are different claims with very different evidence behind them.
04What the evidence shows
The animal literature is genuinely substantial: over a hundred studies across three decades, reporting effects on tendon, ligament, muscle and gut healing. This is where every claim you have read originates.
The human literature is not substantial. A 2025 systematic review in the American Journal of Sports Medicine looking at orthopaedic applications screened 544 articles and found a single clinical study meeting its inclusion criteria.
Animal results do not reliably transfer to humans. Most drugs that work in rodents fail in people, which is why human trials exist. An absence of human trials is not evidence that something works and is being suppressed. It is an absence of evidence, and it means nobody, in either direction, can give you an honest figure for benefit or risk.
Long-term human safety is unknown. There is no approved label, no standardised preparation and no purity standard. Whether grey-market product matches the peptide studied in the literature is unverified in principle, not just in practice.
05Reported harms
No authoritative side effect profile exists, because that comes from regulated trials and a Summary of Product Characteristics, and neither exists here. Absence of reported harms in this situation reflects absence of systematic monitoring rather than demonstrated safety.
The documented risks are the ones that come with unregulated supply: contamination, incorrect identity, inaccurate concentration, non-sterile preparation, and no recall mechanism if something goes wrong.
06Sources
Links go to the primary source. Where a source is behind a paywall or requires registration, the citation is given so you can find it yourself.
- Unlicensed medicines guidanceMHRA
- MHRA investigates clinics over peptide claimsAesthetics Journal, 2026
- Prohibited List, S0 unapproved substancesWADA
- BPC-157 in orthopaedics, systematic reviewAmerican Journal of Sports Medicine, 2025
- BPC 157 and its potential in healing and tissue repairCurrent Pharmaceutical Design, 2011
- BPC-157 creates risk for athletesUSADA
07Change history
Every substantive change to this record is logged here with its date. Corrections are made openly, not quietly.
Loading…
Want telling when this record changes? Follow it from your account.